Company Profile

DR. REDDY'S LABORATORIES LTD.

NSE : DRREDDYBSE : 500124ISIN CODE : INE089A01023Industry : Pharmaceuticals & DrugsHouse : Dr. Reddy's
BSE4757.45-43 (-0.9 % )
PREV CLOSE (Rs.) 4800.45
OPEN PRICE (Rs.) 4826.85
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 116253
TODAY'S LOW / HIGH (Rs.)4720.00 4841.00
52 WK LOW / HIGH (Rs.)4135.9 5613.65
NSE4753.90 -47.9 (-1 % )
PREV CLOSE(Rs.) 4801.80
OPEN PRICE (Rs.) 4801.05
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 4753.90 (305 )
VOLUME 316097
TODAY'S LOW / HIGH(Rs.) 4718.00 4844.45
52 WK LOW / HIGH (Rs.)4135 5614.6

Smart Quotes

1D 1M 3M 1Y 3Y 5Y
STOCK SUMMARY
Trade Value (Rs. in Lacs) 0.06
Dividend Yield(%) 0.53
TTM EPS (Rs.) 99.14
P/E Ratio 47.99
Book Value (Rs.) 1037.90
Face Value (Rs.) 5
MCap (Rs. in Mn) 791634.02
Price/Earning (TTM) 31.87
Price/Sales (TTM) 5.91
Price/Book (MRQ) 4.58
PAT Margin (%) 16.38
ROCE (%) 17.81
Incorporation Year : 1984

Management Info :

K Satish Reddy - Chairman GV Prasad - Managing Director

Registered Office :

Address : 8-2-337,Road No. 3,Banjara Hills,
Hyderabad,
Telangana-500034

Phone : 040 - 4900 2900

Website : www.drreddys.com

Registrar's Details : Bigshare Services Pvt Ltd
306, Right Wing, Amrutha Ville, Opp. Yasodha Hospital,Raj Bhavan Road,Somajiguda,Hyderabad
Listing : BSE, NSE, MCX, New York
NEWS More
19Oct10-19-2021$Dr. Reddy’s gets USFDA’s final approval for Lenalidomide Capsules Dr. Reddy’s gets USFDA’s

Dr. Reddy’s Laboratories has received final approval for its Abbreviated New Drug Application (ANDA) for Lenalidomide Capsules, in 2.5 mg and 20 mg strengths, and tentative approval for 5 mg, 10 mg, 15 mg, and 25 mg strengths, a therapeutic equivalent generic version of REVLIMID (lenalidomide) Capsules, from the U.S. Food and Drug Administration (USFDA). With this approval, the company is eligible for 180 days of generic drug exclusivity for Lenalidomide Capsules, 2.5 mg and 20 mg.

Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.

Dr. Reddy’s Laboratories has received final approval for its..
19Oct10-19-2021$Dr. Reddy's Laboratories informs about press release Dr. Reddy's Laboratories inf

Dr. Reddy's Laboratories has informed that it enclosed a Press Release dated October 19, 2021 ‘Dr. Reddy's Laboratories announces approval for Lenalidomide Capsules from the U.S. Food and Drug Administration (USFDA)’.

The above information is a part of company’s filings submitted to BSE.


Dr. Reddy's Laboratories has informed that it enclosed a Press..
18Oct10-18-2021$Dixon Technologies, Bank of India and Dr. Reddy's to see some action today Dixon Technologies, Bank of
Dixon Technologies has started manufacturing 5G millimetre waves smartphones which will be the first set of devices in the segment to be exported from India. The company has set up a manufacturing unit with an annual capacity of 7 million 5G millimetre (mm) phones and is setting up another factory with annual capacity of 30 million smartphones in Noida.

Bank of India has cut its interest rates on home and vehicle loans by 35 basis point and 50 basis points, respectively. With this cut, the interest rate on home loans starts at 6.50 percent against earlier 6.85 percent, and at 6.85 percent against 7.35 percent prior on vehicle loans. This special rate, which is effective from October 18, 2021, till December 31, 2021, is available for customers applying for fresh loans and also for those seeking transfer of loans.

Dr. Reddy's Laboratories has launched Carmustine for Injection, USP, a therapeutic equivalent generic version of BiCNU (carmustine for injection) approved by the U.S. Food and Drug Administration (USFDA). The BiCNU brand and generic market had U.S. sales of approximately $19.4 million MAT for the most recent twelve months ending in August 2021, according to IQVIA Health. Dr. Reddy's Carmustine for Injection, USP is a lyophilized powder available as a package which includes a single-dose vial containing 100 mg Carmustine USP and a vial containing 3 mL sterile diluent.

Kotak Mahindra Bank (KMBL) is partnering India SME Forum, a not for profit organisation for small and medium enterprises, on its India Xports 2021 initiative supported by the Ministry of Micro, Small & Medium Enterprises, Government of India and the National Small Industries Corporation (NSIC). The initiative aims at supporting Indian MSMEs with a range of exports and trade financing solutions and creating a sustainable exports ecosystem. KMBL is offering a comprehensive array of business banking solutions to all exporters registered under the India Xports initiative.

Rain Industries’ wholly owned subsidiary -- Rain Cements has completed upgradation of Cement mill at Unit -- II, Kurnool District, Andhra Pradesh on October 15, 2021. Consequent to the upgradation of cement mill, the cement grinding capacity is increased from 2.033 million tonnes to 2.795 million tonnes per annum.

Trident Group has commissioned 7.6 MW Solar Power Plant at Budhni, Madhya Pradesh for captive use. Moving towards a greener planet, the Group aims to use renewable and clean energy for reducing carbon emission. This Solar Power Project of 7.6 MW Solar Power is expected to produce 33500 units per day to be consumed in manufacturing facilities located at Budhni, Madhya Pradesh resulting in considerable savings for the company.

Larsen & Toubro (L&T) has launched L&T EduTech -- a new industry-led, application-based, practical oriented learning platform, strongly rooted in technology, that will straddle the entire gamut of engineering & technology verticals to help create industry-ready talent. L&T EduTech aims to future-proof L&T’s businesses and bridge the gap that exists today between the competence of young engineers and industry expectations. L&T EduTech will channelize L&T’s storehouse of knowledge and expertise gained of having executed some of the most complex and demanding projects over the decades to empower both students and professionals with real world professional skilling to enhance their employability.
Dixon Technologieshas started manufacturing 5G millimetre waves..
16Oct10-16-2021$Dr. Reddy's launches Carmustine for Injection, USP in US market Dr. Reddy's launches Carmust

Dr. Reddy's Laboratories has launched Carmustine for Injection, USP, a therapeutic equivalent generic version of BiCNU (carmustine for injection) approved by the U.S. Food and Drug Administration (USFDA).

The BiCNU brand and generic market had U.S. sales of approximately $19.4 million MAT for the most recent twelve months ending in August 2021, according to IQVIA Health. Dr. Reddy's Carmustine for Injection, USP is a lyophilized powder available as a package which includes a single-dose vial containing 100 mg Carmustine USP and a vial containing 3 mL sterile diluent.

Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.

Dr. Reddy's Laboratories has launched Carmustine for Injection,..
16Oct10-16-2021$Dr. Reddy's Laboratories informs about press release Dr. Reddy's Laboratories inf

Dr. Reddy's Laboratories has informed that it enclosed a Press Release dated 15th October 2021 on ‘Dr. Reddy's Laboratories announces the launch of Carmustine for Injection, USP in the U.S. Market’.

The above information is a part of company’s filings submitted to BSE.

Dr. Reddy's Laboratories has informed that it enclosed a Press..
Financials More
Rs. in Millions
QTR Jun 21 ANNUAL 21
Net Profit413421864
Gross Profit 5445 30562
Operating Profit 748139379
Net Sales 34335133491
ROLLING FORWARD P/E (EOD)
EVENT CALENDAR
peer group More
Abbott India (BSE)
 20746.95 (0.93%)
M.Cap ( in Cr)
44085.82
Ajanta Pharma (BSE)
 2215.40 (2.45%)
M.Cap ( in Cr)
19171.13
Sanofi India (BSE)
 8117.95 (0.35%)
M.Cap ( in Cr)
18696.14
Mercury Laboratories (BSE)
 718.00 (3.16%)
M.Cap ( in Cr)
86.16
Suven Pharma (BSE)
 533.95 (1.75%)
M.Cap ( in Cr)
13592.50
Shareholding Pattern More
PROMOTERS 26.73 %
FI/BANKS/INSURANCE 2.66 %
NON-INSTITUTION 16.4 %
MUTUAL FUNDS/UTI 12.42 %
GOVERNMENT 0 %
FII 0 %
F & O Quotes